Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars

Viatris Inc. VTRS on Thursday, released data from Phase 3 study evaluating the contraceptive efficacy and safety of XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential.In this study, XULANE LO demonstrated a favorable efficacy and safety profile; no new safety concerns were identified.The study demonstrated contraceptive efficacy with a Pearl Index (PI) of 4.14. Additionally, the cumulative probability of pregnancy over 1 ...